Iridex Corp (IRIX)
NASDAQ:IRIX
Want to see IRIX full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.01Last Year’s EPS
-0.06Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive picture: solid operational progress (probe and Cyclo G6 growth, cost reductions, partnership expansion, and a near‑term $0.8M backlog) balanced against notable international headwinds, a YoY gross margin decline, softer retina system sell‑through, and a quarter‑end cash decline. Management reaffirmed full‑year guidance ($51M–$53M excluding the Middle East), expects full‑year positive operating cash flow, and highlighted multi‑quarter initiatives (G&A relocation and contract manufacturer transition) that should improve margins over time. Near‑term risks are primarily timing and international/regulatory disruptions rather than fundamental demand weakness in core U.S. businesses.Company Guidance
Stable Quarterly Revenue
Q1 2026 revenue of $11.8M was essentially flat year‑over‑year versus $11.9M in Q1 2025 and came in above prior guidance.
Strong Glaucoma Probe Momentum
G‑Probe unit sales increased to 15.5k from 13.9k year‑over‑year (~+11.5%), reflecting adoption growth and effective MedScout targeting; pricing discipline supported higher ASPs on probes and systems in the U.S.
Cyclo G6 Revenue Growth
Cyclo G6 product family revenue grew to $3.6M from $3.2M year‑over‑year, a reported +14% increase driven by increased units and higher ASPs.
Margin and Cost Initiative Progress
Gross profit was $4.7M representing a 40% gross margin; gross margin improved sequentially by ~300 basis points versus Q4 2025. Operating expenses decreased to $5.1M, down $0.2M or ~4% YoY due to G&A reductions and relocation initiatives.
Corporate and Manufacturing Cost Reductions
Relocation of certain G&A functions began delivering savings (~$100k realized in Q1, ~70% complete) with expected annualized HQ savings of ~$600k. Multiyear transition to lower‑cost contract manufacturers underway with full implementation expected in 2027 to drive future gross margin improvement.
Key Commercial Partnership
Announced iPro GPO partnership in April expanding access to more than 1.8k members (ophthalmology practices, ASC, hospitals) with preferred pricing on retina laser portfolio, increasing addressable market for retina systems.
Backlog as Near‑Term Revenue Opportunity
Approximately $0.8M of deferred retina orders/backlog (primarily due to regulatory and supply timing) expected to ship in Q2, representing an incremental revenue opportunity for the quarter.
IRIX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IRIX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 19, 2026 | $1.05 | $1.00 | -4.76% |
Mar 26, 2026 | $1.35 | $0.99 | -26.67% |
Nov 11, 2025 | $1.19 | $0.95 | -20.17% |
Aug 12, 2025 | $1.30 | $1.18 | -9.23% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Iridex Corp (IRIX) report earnings?
Iridex Corp (IRIX) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Iridex Corp (IRIX) earnings time?
Iridex Corp (IRIX) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IRIX EPS forecast?
IRIX EPS forecast for the fiscal quarter 2026 (Q2) is -0.01.